Skip to main content
OpenTrials
Completed

NCT Number: NCT02046668

The Effect of Spironolactone on Pain in Older People With Osteoarthritis

This pilot study will obtain preliminary evidence on which to base sample size calculations for a future trial of whether spironolactone (an aldosterone blocker) reduces knee pain in older people with symptomatic OA knee when given in addition to usual analgesia. Aldosterone is known to be pro-inflammatory, and spironolactone suppresses cytokine production in chronic arthritis. This application builds on previous work by the applicants showing that spironolactone significantly improved quality of life (particularly pain) in frail older people. The investigators will recruit 86 people (aged 70 years or over) with well-defined OA knee to 25mg spironolactone daily or to matching placebo for 12 weeks. The primary outcome is the between group difference in change in WOMAC pain sub-score at 12 weeks. Secondary outcomes are the WOMAC stiffness and physical function subscales and health related quality of life (EQ-5D). Morning cortisol levels will be measured to assess the effect of mineralocorticoid receptor blockade on glucocorticoid levels, which may mediate the anti-inflammatory effect of spironolactone; and urinary CTX-II, and serum matrix metalloproteinase-3 (MMP-3) will be measured as biomarkers as both are sensitive to the effects of pharmacological interventions for osteoarthritis.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Osteoarthritis, Knee Arthritis Joint Diseases Musculoskeletal Diseases Osteoarthritis Rheumatic Diseases

Age range

70 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 4

Primary location

NHS Fife, Kirkcaldy, Fife, United Kingdom

Loading trial locations.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Participant is willing and able to give informed consent
  • Community dwelling
  • Aged 70 years and over
  • Symptomatic idiopathic OA knee according to American College of Rheumatology clinical and radiographic criteria (ie Knee pain - with or without crepitus and presence of osteophytes on x ray)
  • To avoid floor effects, participants will require to have moderate (or more severe) pain at screening in at least 2 out of 5 WOMAC pain score items
  • To have been in receipt (prescription or/and over the counter) of one or more analgesic agents at a therapeutic dose for at least 2 months
  • Willing to have knee x-ray if one has not been taken in preceding 12 months

Exclusion criteria

  • Clinical diagnosis of symptomatic heart failure
  • History of inflammatory arthritis
  • Already taking spironolactone
  • Previous intolerance to spironolactone
  • Known allergies to spironolactone or lactose
  • Objection to taking capsules made from animal sourced gelatine
  • Taking oral NSAIDs (because of the increased risk of renal impairment when combined with spironolactone)
  • Taking ACE inhibitors or ARBs (angiotensin II receptor antagonists). ARBs have many properties similar to those of ACE inhibitors. Both will be exclusion because of the increased risk of acute kidney injury and hyperkalaemia, and because our previous study also excluded those on ACE inhibitors (and ARBs) and treatment was safe and well tolerated.
  • Supine hypotension (supine systolic blood pressure <100mmHg at screening)
  • Significant chronic kidney disease (eGFR<40ml/min)
  • Serum sodium<130mmol/l
  • Serum potassium>5.0mmol/l
  • Symptomatic orthostatic hypotension (measured at screening)
  • Nursing home resident
  • Wheelchair bound
  • Participating in another clinical trial (other than observational trials and registries) concurrently or within 30 days prior to screening for entry into this study
  • Known contraindication to spironolactone therapy
  • Participant who is terminally ill, defined as less than 3 months expected survival

Treatment and study plan

Spironolactone

Drug

spironolactone 25mg daily for 12 weeks

Other names: Aldactone

Primary outcomes

  1. Between group difference in change in WOMAC pain subscale (5 items)

    Time frame: 12 weeks

Secondary outcomes

  1. Between group difference in change in WOMAC stiffness subscale.

    Time frame: 12 weeks

Other outcomes

  1. Between group difference in change in WOMAC physical function subscales.

    Time frame: 12 weeks

  2. Between group difference in change in health-related quality of life measured by EQ-5D questionnaire.

    Time frame: 12 weeks

Sponsors and collaborators

Lead sponsor

University of Dundee

Other

Collaborators

  • Arthritis Research UK

Registry information

Official study title

A Randomised Placebo Controlled Trial. The Effect of Spironolactone on Pain in Older People With Osteoarthritis

Acronym: SPIR-OA

Important dates

Study start
2013
Primary completion
2015
Study completion
2015
First posted
Jan 28, 2014
Registry last updated
Oct 14, 2019

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.